DavidLincolnDiuguidMD

PubMed

• ASH living guidelines on use of anticoagulation for thromboprophylaxis in patients with COVID-19: executive summary.
  Deborah M Siegal, Eric K Tseng, Holger J Schünemann, Pantep Angchaisuksiri, Adam Cuker
  Blood Advances. 2024-10-22
• 43 citations
  American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of ther...
  Adam Cuker, Eric K Tseng, Robby Nieuwlaat, Pantep Angchaisuksiri, Clifton Blair
  Blood Advances. 2022-09-13
• 24 citations
  American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of antic...
  Adam Cuker, Eric K Tseng, Holger J Schünemann, Pantep Angchaisuksiri, Clifton Blair
  Blood Advances. 2022-09-13

Journal Articles

• Clotting and Bleeding in Oncology Patients: Clinical Scenarios and Challenges  
  Komatsubara, KM and Diuguid DL, Oncology, 1/1/2016
• Prior hematologic conditions carry a high morbidity and mortality in patients supported with continuous-flow left ventricular assist devices  
  Fried J, Levin AP, Mody KM, Garan AR, Yuzefpolsakaya M, Takayama H, Diuguid DL, Naka Y, Jorde U, Uriel N, J Heart Lung Transplant, 1/10/2014
• Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience  
  Pham HP, Hsu SX, Parker-Jones S, Samstein B, Diuguid D, Schwartz J, Vox Sang, 1/1/2014
• A severe case of cefoxitin-induced hemolytic anemia  
  Leaf, DE, Langer, NB, Markowski, M, Garratty, G, and Diuguid, DL, Acta Haematologica, 1/1/2010
• Worth a second look  
  Goldberg D. Weisberg I. Diuguid D. Gaglio P. Alobeid B. Fink S. Radhakrishnan J., American Journal of Medicine, 1/1/2009
• The spectrum of myelodysplastic syndromes post-solid organ transplantation: a single institutional experience  
  Menes M., Vakiani E., Keller CE., Ho EK., Colovai A., Nichols G., Diuguid D., Mears JG., Murty VV., Alobeid B., and Bhagat G, Leukemia Research, 1/1/2007
• Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient  
  Leykum, L., Pugh, J., Diuguid, D, and Papadopoulos, K, Journal of Hospital Medicine, 1/1/2006
• Off-pump right atrial thrombectomy for heparin-induced thrombocytopenia with thrombosis  
  Morgan, JA. Kherani, AR, Vigilance, DW, Cheema, FH, Colletti, NJ, Sahar, DI, Jan, KM, Diuguid, DL, Nowygrod, R, Oz, MC, and Argenziano, M, Annals of Thoracic Surgery, 1/1/2003
• Prevention of venous thromboembolism with fondaparinux Reply to Letter to the Editor  
  Diuguid, DL, New England Journal of Medicine, 1/1/2002
• Choosing a Parenteral Anticoagulant Agent  
  Diuguid, DL, New England Journal of Medicine, 1/1/2001
• Oral Anticoagulant Therapy for Venous Thromboembolism Reply to Letter to the Editor  
  Diuguid, DL, New England Journal of Medicine, 1/1/1997
• Oral Anticoagulant Therapy for Venous Thromboembolism  
  Diuguid, DL, New England Journal of Medicine, 1/1/1997
• Protein S Deficiency in Pregnancy: A Case Report  
  Tharakan, T, Baxi, LV, and Diuguid, D., American Journal of Obstetrics and Gynecology, 1/1/1993
• Randomized prospective trial comparing the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy  
  Furie, B., Diuguid, C.F., Jacobs, M., Diuguid, D.L., and Furie, B.C., Blood, 1/1/1990
• Factor IX San Dimas: Substitution of glutamine for arginine -4 in the propeptide leads to incomplete ?-carboxylation and altered phospholipid binding properties  
  Ware, J., Diuguid, D.L., Liebman, H.A., Rabiet, M.J., Kasper, C.K., Furie, B.C., Furie, B., and Stafford, D.W., J Biol Chem, 1/1/1989
•  
  Diuguid, D.L., Rabiet, M.J., B.C. Furie, and B. Furie, Blood, 1/1/1989
• Molecular basis of Hemophilia B: A defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor  
  Diuguid, D.L., Rabiet, M.J., Furie, B.C., Liebman, H.A., and Furie, B, Proc Natl Acad Sci, USA, 1/1/1986
• The action of thrombin on blood clotting factor V: conversion of factor V to a prothrombin binding protein  
  Esmon, C.T., Owen, W.G., Duiguid, D.L., and Jackson, C.M., Biochimica et Biophysica Acta, 1/1/1973
• Join now to see all

Books/Book Chapters

• Hematology: Basic Principles and Practices. 
  Chapter: Molecular genetics of hemophilia B. 
  Page 1316 - 1324Diuguid, D.L. and Furie, B.Editors: Hoffman, R., Benz, E.J., Shattil, S., Furie, B., and Cohen, H.J..Churchill Livingstone Inc., New York, NY1991

Abstracts/Posters

• Severe HIV-Associated Bleeding and Platelet Dysfunction in the Absence of Thrombocytopenia: A Report of 2 Cases.
  Noy, A and Diuguid, D, Blood, 1/1/1996
• Increased frequency of lupus anticoagulant in stroke patients with aortic arch atheromas.
  DiTullio, M, Sacco, RL, Santoni-Fighu, F, Gersony, D, Nayak, H, Kargman, D, Sherman, D, Weslow, R, Diuguid, D, & Homma, S, Neurology, 1/1/1995
• Patent foramen ovale and hypercoagulable states in ischemic stroke patients.
  DiTullio, MR, Santoni-Righu, F, Sacco, RL, Sherman, D, Diuguid, D, Weslow, RG, Leibowitz, DW, Shapiro, GC, & Homma, S, Circulation, 1/1/1994
• Randomized Prospective Trial Comparing the Native Prothrombin Antigen and the Prothrombin Time for Monitoring Oral Anticoagulant Therapy.
  Furie, B., Diuguid, C.F., Jacobs, M., Diuguid, D.L., and Furie, B.C., Blood, 1/1/1988
• Factor IX Cambridge: Hemophilia B caused by an unprocessed leader sequence on the Factor IX NH2 terminus.
  Diuguid, D.L., Rabiet, M.J., Liebman, H.A., Furie, B.C., and Furie, B., Blood; American Society of Hematology, 1/1/1985
• Join now to see all